Delayed graft function (DGF) a complication of early graft dysfunction often follows organ transplantation. Targeting this condition, a novel antibody treatment may prevent loss of graft function and ultimately transplant failure.
DGF incidence ranges from 40-60 % in high-risk kidneys, depending on organ donor state, and occurs when blood supply returns after lack of oxygen, ischaemia-reperfusion injury. Dialysis can be required for about seven days until the organ regains its function, increasing the chances of transplant failure.
Further details: Antibody for prevention of Early graft dysfunction in high risk cadaveric kidneys